Digital Biomanufacturing Market Report 2025

The digital biomanufacturing market size has grown rapidly in recent years. It will grow from $21.11 billion in 2024 to $23.82 billion in 2025 at a compound annual growth rate (CAGR) of 12.8%. The growth in the historic period can be attributed to increasing complexity of biopharmaceuticals, rise in personalized medicine, demand for cost-effective production, bioprocess optimization, quality control and regulatory compliance.

The digital biomanufacturing market size is expected to see rapid growth in the next few years. It will grow to $40.43 billion in 2029 at a compound annual growth rate (CAGR) of 14.1%. The growth in the forecast period can be attributed to blockchain for supply chain transparency, advanced process control (APC) systems, emphasis on sustainability, interconnected biomanufacturing ecosystems, biomanufacturing in emerging markets. Major trends in the forecast period include integration of artificial intelligence (AI), digital twins for bioprocessing, advancements in biotechnology, Industry 4 integration, real-time monitoring and control.

The increasing demand for biologics is projected to drive the growth of the digital biomanufacturing market in the coming years. Biologics encompass a broad range of pharmaceuticals, including vaccines, growth factors, immunological modulators, monoclonal antibodies, and drugs derived from human blood and plasma. Digital biomanufacturing enhances the production of biologics by optimizing processes, improving quality control, reducing costs, and shortening production times. This approach enables producers to adopt data-driven methodologies and advanced technologies to meet the rising demand for biologics more efficiently and sustainably. For instance, in February 2023, Cell & Gene, a U.S.-based online resource for research scholars, reported that there were 27 FDA-approved cell and gene therapies (CGTs), representing approximately 8% of the 340 approved biologics in 2022, an increase from 22 approvals in 2021. Thus, the growing demand for biologics is a key driver of the digital biomanufacturing market.

The thriving pharmaceutical industry is expected to fuel growth within the digital biomanufacturing market. Amid the dominance of North America in global pharmaceutical sales at 52.3% and Europe at 22.4% in June 2023, the United States witnessed a majority of new medicine sales compared to Europe's top five markets. This trend toward increased efficiency and productivity in pharmaceutical manufacturing propels the digital biomanufacturing sector.

Technological advancements act as trend in digital biomanufacturing. In October 2022, PharmNXT Biotech LLP, an India-based biotech startup, has launched its first integrated manufacturing unit in Pune to provide single-use bioprocessing solutions. The state-of-the-art facility has been launched to address the challenges of biologics manufacturing in the country. The new facility will generate employment opportunities for over 100 to 200 people and will cater to the demands from global markets such as Singapore, Korea, Europe & the US. The ekuse manufacturing facility will be engaged in crafting the Xelta range of single-use bioprocessing products and ‘NXTmix’ a levitating mixing technology.

Prominent companies operating in the market are undergoing into strategic collaborations to sustain their position in the market. Strategic collaborations promote collaboration, innovation, and efficiency in the digital biomanufacturing market, fostering an environment conducive to growth and technological advancement. In January 2022, Scitara DLX partnered with BioPhorum to drive scientific advancements in the digital biomanufacturing market. This collaboration aims to accelerate innovation, facilitate knowledge exchange, and offer standardized cloud-based platforms for enhanced communication and data exchange.

In April 2022, Bruker Corporation, a U.S.-based company specializing in scientific instruments for molecular and materials research, acquired Optimal Industrial Automation and Technologies for an undisclosed amount. This strategic acquisition is designed to bolster Bruker's capabilities in offering software and solutions specifically tailored for the biopharmaceutical industry. Optimal Industrial Automation and Technologies is a U.K.-based provider of pharmaceutical process analytical technology (PAT) and manufacturing automation.

Major companies operating in the digital biomanufacturing market include Sanofi SA, Thermo Fisher Scientific Inc., Honeywell International Inc., 3M Company, SAP SE, Danaher Corporation, ABB AG, Siemens Healthineers AG, Emerson Electric Co, GE HealthCare Technologies Inc., Atos SE, Agilent Technologies Inc., Cytiva Europe GmbH, Lonza Group AG, Dassault Systèmes SE, Sartorius AG, BioMérieux, Donaldson Company Inc., Pall Corporation, Eppendorf AG, Symphony Innovation LLC, Koch Membrane Systems Inc., Culture Biosciences Inc., Bota Biosciences Inc., Shimadzu Corporation, e-MSion, Exponential Genomics Inc., Immersciobio GmbH.

North America was the largest region in the digital biomanufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global digital biomanufacturing market during the forecast period. The regions covered in the digital biomanufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the digital biomanufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Digital biomanufacturing leverages digital technologies to enhance efficiency and innovation in biomanufacturing processes.

Digital biomanufacturing encompasses various types of technologies aimed at improving manufacturing quality, productivity, and practices in the production of biological products. These technologies, including AI, IoMT solutions, process analytical tools, data analytics software, and digital twin technologies, are utilized to optimize bioprocesses, automate manufacturing, and enhance control. Biopharmaceutical companies, academic institutions, and research institutes leverage these advancements to produce antibodies, cell and gene therapies, proteins, vaccines, and other biologics with improved efficiency, product quality, and scalability.

The digital biomanufacturing market research report is one of a series of new reports that provides digital biomanufacturing market statistics, including digital biomanufacturing industry global market size, regional shares, competitors with a digital biomanufacturing market share, detailed digital biomanufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the digital biomanufacturing industry. This digital biomanufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The digital biomanufacturing market consists of revenues earned by entities by providing various technologies that support the manufacturing of biologics such as big data, cloud computing, lean product and process development, sensor technologies, process control, and enterprise control. The market value includes the value of related goods sold by the service provider or included within the service offering. The digital biomanufacturing market also includes sales of sensors, analyzers, and actuators and process control systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.